Upload
orenmind
View
221
Download
0
Embed Size (px)
Citation preview
8/9/2019 Idris - Biosis Group Berhad2
1/9
BIOSIS GROUP BERHAD2
Business profle
Biosis Group Berhad is engaged in investment holding and the provision of
management services. The Company operates in four segments: Personal
and health care products, which is engaged in the manufacturing, marketing,
trading and distribution of personal care products and health care products
Pharmaceutical products, which is engaged in the manufacturing, marketing,
trading and distribution of pharmaceutical products !irect selling, which is
engaged in direct selling and marketing of health and food supplements and
personal care products, and "thers include investment holding and inactive
companies. #ts subsidiaries include Biosis Cosmeceuticals $dn. Bhd., Biosis
%arketing $dn. Bhd., Biosis Pharmaceuticals $dn. Bhd. Biosis %arketing &'()
Pte. *td. and !+'air $hop &%) $dn. Bhd.
Biosis Group Berhad, &Biosis) formerly 'iCity Bioscience Group Berhad,
manufactures, markets and distributes personal care, health care, and
pharmaceutical products. The company+s o-ering includes pharmaceuticals,
medical devices and life science products, body care products, hair care
products, oral care products, foot care products and skin care and cosmetics.
The company also entered into direct retail marketing of personal care
products through its subsidiary !+'air $hop &%) $dn. Bhd. The company is
headuartered at Penang, %alaysia.
The company+s strategy is to enhance its o-ering portfolio and entering into
new market by introducing new products, enhancing its e/isting products.
The company disposed Biosis Pharmaceuticals $dn. Bhd. as the subsidiary
was not able to ful0ll certain conditions.
8/9/2019 Idris - Biosis Group Berhad2
2/9
Biosis Group Berhad : Practice Note !
Pursuant to paragraph 1.23 and paragraph 4.5&e) of Practice 6ote 57
&8P6578) the %ain %arket *isting 9euirements &8%%*98) of Bursa %alaysia
$ecurities Berhad &8Bursa $ecurities8) where the auditors have e/pressed an
emphasis of matter on B#"$#$+ ability to continue as a going concern in the
latest audited 0nancial statements, the Board of !irectors of B#"$#$ wishes
to announce that B#"$#$ is considered as a P657 Company.
The P657 criteria triggered as a result of the Company+s latest unaudited
accounts for the 0nancial year ended 5 %arch 425 that was announced on
5 %ay 425 where the Company+s shareholders+ euity on a consolidated
basis is ;2< or less of the issued and paidup capital &=the >irst
?nnouncement@).
OB"IGA#IONS O$ #HE %O&PAN' PURSUAN# #O PN!
Pursuant to paragraph 1.23&) of the %%*9, B#"$#$ is reuired to comply
with the following:
&i) ?nnounce within months from the >irst ?nnouncement, on whether the
regularisation plan will result in a signi0cant change in the business direction
or policy of the Company
&ii) Aithin 54 months from the date of the >irst ?nnouncement:
8/9/2019 Idris - Biosis Group Berhad2
3/9
&a) submit a regulariation plan to the $ecurities Commission &8$C8) if the
plan will result in a signi0cant change in the business direction or policy of
the Company
&b) submit a regulariation plan to Bursa $ecurities if the plan will not resultin a signi0cant change in business direction or policy of the Company, and
obtain Bursa $ecurities approval to implement the plan.
&iii) #mplement the regulariation plan within the time frame stipulated by the
$C or Bursa $ecurities, as the case may be
&iv) ?nnounce the status of its regulariation plan and the number of monthsthe end of the relevant time frames referred in paragraphs ;.5 and ;.4 of
P657, as may be applicable, on a monthly basis until further notice from
Bursa $ecurities
&v) ?nnounce its compliance or noncompliance with a particular obligation
imposed pursuant to P657, on immediate basis
&vi) ?nnounce the details of the regulariation plan &89euisite
?nnouncement8) and suDcient information to demonstrate that the
Company is able to comply with all the reuirements set out in paragraph .5
of P657 after implementation of the regulariation plan. The 9euisite
?nnouncement must be made by the Companys Principal ?dviser and
&vii) Ahere the Company fails to regularie its condition, it will announce the
dates of suspension and delisting of its listed securities immediately uponnoti0cation of suspension and delisting by Bursa $ecurities.
. C"6$EFE6CE$ "> 6"6C"%P*#?6CE "> A#T' T'E "B*#G?T#"6$
8/9/2019 Idris - Biosis Group Berhad2
4/9
#n the event the Company fails to comply with the obligations to regularise
its condition, all its listed securities will be suspended from trading on the
ne/t market day after 0ve &;) market days from the date of noti0cation of
suspension and delisting by Bursa $ecurities and delisting procedures shall
be taken against the Company, subHect to the Companys right to appeal
against delisting.
3. $T?T$ "> 9EG*?9#$?T#"6 P*?6
The Company intends to formulate a regularisation plan to address its P657status and this will be announced to Bursa $ecurities in due course.
This announcement is dated 26 June 2013.
Balance sheet
n millions of MYR(except for per share items)Annual dataInterim data
Fiscal data as of Mar 31 2014 2014 2013 2012
ASSETS
ash And !hort "erm In#estments 0$4% 0$31 0$3&
"otal Recei#a'les et 3$34 1% 1*
"otal In#entor+ 2$2& %$,- -$,*
.repaid expenses // 0$3& 0$-0
ther current assets total // 13 0$&3
Total current assets 6.08 34 27
.ropert+ plant euipment net 2% 2& 4-
oodill net // // //
Intan5i'les net // 3$0, 3$22
8/9/2019 Idris - Biosis Group Berhad2
5/9
Fiscal data as of Mar 31 2014 2014 2013 2012
6on5 term in#estments 2$%3 2$%, 2$4,
ote recei#a'le / lon5 term // 3$4& ,$&&
ther lon5 term assets // // //
Total assets 34 73 87
LIABILITIES
Accounts pa+a'le 4$0, 3$-2 4$&3
Accrued expenses // 2$,% 2$24
otes pa+a'le7short/term de't 33 -$23 1%
urrent portion lon5/term de't7capital leases // 1, 11
ther current lia'ilities total 21 1% ,$33
Total current liabilities 57 45 39
"otal lon5 term de't 1$00 12 14
"otal de't 34 3% 40
Deerre! inco"e ta# 0.$8 $.05 $.53
Minorit+ interest 0$*0 (0$&3) 0$1%
ther lia'ilities total 0$34 0$%1 0$,*
Total liabilities 60 57 56
S%A&E%'LDE&S E()IT*
ommon stoc8 %3 %3 %3
Additional paid/in capital 0 0 0
Retained earnin5s (accumulated deficit) (-*) (40) (24)
"reasur+ stoc8 / common // // //
9nreali:ed 5ain (loss) // 2$2* 2$2*
ther euit+ total (0$12) (0$12) (0$0%)
Total e+uit, -26 $5 3$
Total liabilities / sareol!ers1 e+uit, 34 73 87
"otal common shares outstandin5 10% 10% 10%
"reasur+ shares / common primar+ issue 0 0 0
8/9/2019 Idris - Biosis Group Berhad2
6/9
%ash $lo(
In millions of MYR(except for per share items)Annual dataInterim data
Fiscal data as of Mar 31 2014 2014 2013 2012
'E&ATI'S
et income (40) (1-) (22)
;epreciation7depletion 2$*4 4$&0 *$10
on/ash items 30 %$*, *$03
ash taxes paid supplemental (0$02) 0$12 0$00
ash interest paid supplemental 0$3* 1$,% 2$4-
han5es in or8in5 capital 1$,0 11 ,$&,
Total cas ro" oerations -5.55 4.53 $.06
IESTI
aital e#en!itures -0.0$ -0.26 -0.54
ther in#estin5 and cash flo items total 12 (0$0&) 3$&-
Total cas ro" inestin $2 -0.35 3.43
:IAI
Financin5 cash flo items 0$%4 0$23 (0$%2)
Total cas !ii!en!s ai! ;; ;; ;;
Issuance (retirement) of stoc8 net // 0 2$%0
Issuance (retirement) of de't net (%$*0) (3$00) (&$-%)
Total cas ro" inancin -5.26 -2.77 -7.77
ET %AE I AS%
Forei5n exchan5e effects 0$00 0$00 0$01
et cane in cas $.54 $.42 -3.27
et cash/'e5in 'alance7reser#ed for future use (3$24) (4$,,) (1$3&)
et cash/end 'alance7reser#ed for future use (1$-0) (3$24) (4$,,)
8/9/2019 Idris - Biosis Group Berhad2
7/9
Fiscal data as of Mar 31 2014 2014 2013 2012
S)LE
8/9/2019 Idris - Biosis Group Berhad2
8/9
Fiscal data as of Mar 31 2014 2014 2013 2012
ES &E'ILIATI'
8/9/2019 Idris - Biosis Group Berhad2
9/9
"in)s*re+erence
http:IImarkets.ft.comIresearchI%arketsITearsheetsI>inancialsJsKB#"$#$:(*$
http://markets.ft.com/research/Markets/Tearsheets/Financials?s=BIOSIS:KLShttp://markets.ft.com/research/Markets/Tearsheets/Financials?s=BIOSIS:KLS